Survodutide
Also known as: BI 456906
Dual glucagon/GLP-1 receptor agonist; promotes weight loss via appetite suppression + increased energy expenditure from glucagon activity.
- Typical dose
- 600 mcg – 6 mg
- Frequency
- once weekly
- Route
- Subcutaneous
- Half-life
- 6.5 days
- Routes
- Subcutaneous
- Status
- Investigational: Phase III
Benefits
- Significant weight loss
- Liver fat reduction (MASH)
- Metabolic improvement
- Dual-action mechanism
Dosing
A common research range for Survodutide is 600 mcg to 6 mg once weekly. Titrate from 0.6mg to 4.8-6.0mg weekly over 16 weeks. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Survodutide has an approximate half-life of 6.5 days. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.
Storage
2-8°C.
Reported side effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
Contraindications
- MEN2
- Pancreatitis
- Medullary thyroid carcinoma
Track Survodutide with Vial
Vial logs every Survodutide dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Survodutide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.